Real-world study of Nasoclear PureHale in sino-nasal symptoms
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: J399- Disease of upper respiratory tract, unspecified
- Registration Number
- CTRI/2022/07/043751
- Lead Sponsor
- Zydus Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Data of a patient will be copied in the data collection form only if:
1. Patient had an indication for application of hypertonic saline nasal sprays, including but not limited to, e.g., viral, bacterial, or allergic rhinitis, acute or chronic rhinosinusitis
2. The patient had symptoms of nasal congestion at his/her initial visit (Visit 0) at the medical center.
3. The Total Nasal Symptom Score (TNSS) of the patient was recorded as >= 5 at visit 0.
4. The patient was eligible to receive and was prescribed Nasoclear PureHaleTM as per the physicianâ??s discretion.
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method There is no primary outcome measure nor any formal sample size calculation. Descriptive statistics will be utilized to analyze data from the data collection form.Timepoint: Baseline and Visit 1 <br/ ><br>Visit 1 can be between day 5 to day 10 after baseline visit
- Secondary Outcome Measures
Name Time Method o defined secondary outcomeTimepoint: No defined secondary outcome